drugset / Trial / NCT07499037
Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO
Phase 2
Not yet recruiting
200 enrolled
University Hospital Ostrava
University Hospital, Motol · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The standard and most common therapy is anticoagulation with heparin according to activated partial thromboplastin time (aPTT) during extracorporeal membrane oxygenation (ECMO) support. The study will focus on evaluating the efficacy and safety of new anticoagulants on ECMO, namely argatroban and enoxaparin in lower doses controlled according to targeted antiIIa and antiXa markers.
Timeline
- Start
- 2027-01
- Primary completion
- 2029-09
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Argatroban | Small molecule | — | — |
| Subject | Enoxaparin sodium | Other / unclassified | — | — |